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DAPATAN TERAPEUTIK DAN MORTALITI YANG BERKAITAN 
DENGAN HEMODIALISIS DALAM KALANGAN PESAKIT HIPERTENSI 
DAN DIABETES DI JAKARTA, INDONESIA DAN PENANG, MALAYSIA 
 
ABSTRAK 
Dapatan terapeutik pesakit hemodialysis biasanya bergantung kepada 
farmakoterapi yang betul yang diberikan dan susulan pesakit. Berdasarkan kejadian 
kematian yang tinggi dalam kategori ini, satu kajian telah dijalankan di kedua-dua 
negara, Indonesia dan Malaysia. Sejumlah 455 pesakit dari pusat HD Jakarta dan 
Pulau Pinang telah dimasukkan ke dalam kajian ini berdasarkan kriteria inklusi dan 
pengecualian. Penilaian retrospektif sebanyak 199 pesakit di kedua-dua negara turut 
dimasukkan. Semua pesakit yang memenuhi kriteria telah dimasukkan ke pusat HD 
Pulau Pinang dan Jakarta sebagai kemudahan sampling. Dalam 256 pesakit 
hemodialysis yang dinilai, 14.8% mempunyai diabetes mellitus, 55.1% mempunyai 
hipertensi dan 30.1% mempunyai diabetes mellitus dan hipertensi. Semua data yang 
dihasilkan pada borang pengumpulan data yang sah dan juga semua pesakit telah 
diwawancara secara prospektif melalui soal selidik yang telah ditetapkan. Kesemua 
pesakit akan disusuli selama sembilan bulan di kedua-dua pusat tersebut. 
Berdasarkan penilaian KDQoL-SF24, perbezaan antara pusat-pusat HD di Jakarta 
dan Pulau Pinang didapati dalam beban penyakit buah pinggang, status kerja dan 
sokongan sosial. Walau bagaimanapun, penilaian kesihatan keseluruhan bagi kedua-
dua negara adalah lebih daripada markah standard (> 59.37 ± 19.54). Tempoh 
penyakit kardiovaskular meningkatkan risiko kematian lebih daripada 2 kali di 
kedua-dua pusat Indonesia dan Malaysia semasa waktu susulan. Di samping itu, 
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pesakit yang menjalani hemodialisis di Indonesia menunjukkan hubungan yang 
signifikan (P = 0.006) antara tempoh penyakit kardiovaskular dan risiko kematian 
dengan 23% daripada pesakit ini mempunyai tempoh penyakit kardiovaskular ≤ 5 
tahun dan hanya 3.4% daripada pesakit ini mempunyai tempoh penyakit 
kardiovaskular ≥ 6 tahun. Hasilnya menunjukkan bahawa tiada ruang berasingan 
untuk pesakit hemodialysed yang mempunyai hepatitis C di pusat HD Jakarta, 
Indonesia. Bagaimanapun, di pusat HD di Pulau Pinang, Malaysia, bilik berasingan 
wujud bagi pesakit yang mempunyai hymodylised yang mempunyai hepatitis C. 
Keadaan di atas menerangkan peningkatan hepatitis di kalangan pesakit hemodialis 
di pusat HD Jakarta, Indonesia (pemeriksaan hepatitis C pertama mencatatkan 46 
pesakit hemodialysed hepatitis C manakala tindak lanjut kedua menyaksikan 
bilangan pesakit meningkat kepada 60). Tambahan pula, 34% pesakit hemodialisis 
mempunyai hepatitis selepas susulan dan 58,38% pesakit meninggal dengan 
komplikasi hepatitis. Lebih-lebih lagi, lebih daripada 70% pesakit di Pulau Pinang 
diberi suplemen untuk menyokong farmakoterapi keadaan hemodialysed manakala 
beberapa kes telah diperhatikan di Jakarta. Ini mengakibatkan kadar mortaliti (35%) 
yang lebih tinggi di Jakarta sedangkan di Pulau Pinang kurang daripada 12% 
kematian didapati. Perbezaan dalam peruntukan sistem farmakoterapi dan penjagaan 
kesihatan antara kedua-dua negara menyumbang kepada perubahan dalam hasil 
terapeutik. Oleh itu, pesakit di Pulau Pinang mempunyai kualiti kehidupan yang 
lebih baik, kadar kelangsungan hidup dan kurang komplikasi berbanding Indonesia. 
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THERAPEUTIC OUTCOMES AND MORTALITY RELATED TO 
HEMODIALYSIS AMONG HOSPITALIZED HYPERTENSIVE AND 
DIABETIC PATIENTS IN JAKARTA, INDONESIA AND PENANG, 
MALAYSIA 
 
ABSTRACT 
Therapeutic outcomes of hemodialysed patients usually depend on proper 
pharmacotherapy given and follow up of the patients. Based on the high mortality 
incidence of this category, a study was conducted in both countries, Indonesia and 
Malaysia. A total of 455 patients from HD center Jakarta and Penang were included 
in this study based on inclusion and exclusion criteria. A retrospective evaluation of 
199 patients in both countries were also included. All patients that fulfilled the 
criteria were included in HD center Penang and Jakarta as convenience sampling. In 
256 hemodialysed patients who were evaluated by prospective, 14.8 % had diabetes 
mellitus, 55.1% had hypertension and 30.1 % had diabetes mellitus and hypertension. 
All the data was produced on a validated data collection form and also all the patients 
were interviewed prospectively through an already established questionnaire. All the 
prospective patients were followed up for nine months in both centers. Based on the 
assessment of KDQoL-SF24, the differences between HD centers in Jakarta and 
Penang were found in the burden of kidney disease, work status and social support. 
However, overall health rating for both countries were more than standard score (> 
59.37 ± 19.54). Duration of cardiovascular disease elevated risk of death more than 2 
times in both centers of Indonesia and Malaysia during the follow up time. In 
addition, patients who undergone hemodialysis in Indonesia showed significant 
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relationship (P =0.006) between duration of cardiovascular and probability of dying 
with23% of these patients had duration of cardiovascular diseases ≤ 5 years and only 
3.4 % of these patients had duration of cardiovascular diseases ≥ 6 years. The result 
further indicated that there was no separate room available for hemodialysed patients 
with hepatitis C in HD center Jakarta, Indonesia. However, at the HD center in 
Penang, Malaysia, a separate room existed for hymodylised patients having hepatitis 
C. The above situation explains the increase of hepatitis among hemodialysed 
patients in HD center Jakarta, Indonesia (the first hepatitis C check noted 46 
hemodialysed patients having hepatitis C while the second follow up saw number of 
patients increased to 60). Furthermore, 34 % hemodialysed patients had hepatitis 
upon follow up and 58.38% patients died with hepatitis complication. Moreover, 
more than 70 % patients in Penang were given supplement to support the 
pharmacotherapy of the hemodialysed condition while very few cases were noted in 
Jakarta. This resulted in higher mortality (35%) rate in Jakarta whereas in Penang 
less than 12 % of mortality were found. The differences in pharmacotherapy and 
healthcare system provisions between the two countries contributed to the variation 
in the therapeutic outcomes. Thus, patients in Penang have better quality of life, 
survival rate and less complication compared to Indonesia. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Introduction 
 
Hemodialysis is one of the processes in replacing kidney function (Sitprija, 
2003). Patients who are doing hemodialysis will be engaged with this treatment for a 
long time or may be as long as their life (Koda-Kimble, Mary Anne, Young LY, 
Alldrege, BK, Corelli, RL, Guglielmo, BJ, Kradjan, WA, Williams, 2008). 
Prevalence and mortality of hemodialysis are found all over the world (Anand, 
Khanam, & Finkelstein, 2014). Indonesia and Malaysia are not exempted on this 
(Indonesian Renal Registry, 2014) (Ministry of Health Malaysia, 2012). 
Usually patients who requiring hemodialysis are patients with End-Stage 
Renal Disease (ESRD) and  this disease is a worldwide public health problem 
(Kidney, 2014) and it is the final stage of chronic kidney disease (Dasari, 
Venkateshwarlu, & Venisetty, 2014). At this stage, the kidneys are no longer able to 
remove enough wastes and excess fluids from the body (Dasari et al., 2014). There 
are some risk factors for ESRD such as dietary habit, using of drugs in a long time, 
loss of body fluid, infection, complication of disease and family history (Koda-
Kimble, Mary Anne, Young LY, Alldrege, BK, Corelli, RL, Guglielmo, BJ, Kradjan, 
WA, Williams, 2008). Taking a good care for this disease will minimize the 
complication, which can occur among patients on hemodialysis. 
The most common risk factors for ESRD are diabetes and hypertension 
(Indonesian renal Registry, 2012; Ministry of Health Malaysia, 2013). The 
prevalence of diabetes, metabolic risk factors and other indicators of renal disease 
provided an increased understanding of the burden of kidney disease within the 
Australian community, and applicable worldwide (Kidney Health Australia, 2016). 
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Almost in each country, ESRD prevalence increases every year (Arikan & Tuglular, 
2005). ESRD affects over 400,000 patients in North America requiring dialysis 
(Lacson et.al, 2012).  Moreover, it is increasing as many as 25 million people in the 
United States, and more than 500,000 have end-stage renal disease (Pinho, Silva, & 
Pierin, 2015; United States Renal Data System, 2015). According to the Karger 
study, at least 2.9 million people need dialysis in Asia based on modelling data 
suggestion (Prasad, 2015). 
Hemodialysis improves serum creatinine, albumin and prealbumin, 
normalizes the protein catabolic rate (nPCR) as well as increases the dietary intake of 
patients (Himmelfarb & Ikizler, 2010). Despite modern technology and medicines, 
mortality on dialysis continues to be high with an average 5-year survival of 
approximately 33% and 50% of patients with and without diabetes respectively 
(Lacson et.al, 2012). There is a high prevalence patients undergoing hemodialysis all 
over the world is one of the big problems and can be solved while minimizing the 
risk factors. Furthermore, mortality rate has also increased in undergoing 
hemodialysis (CDC & Centers for Disease Control and Prevention, 2014; Committee 
& Akiba, Takashi; Nakai, Shigeru; Shinzato, Toru; Yamazaki, Chikao; Kitaoka, 
Tateki; Kubo, Kazuo; Maeda, 2000).  
Patient condition should be considered prior to hemodialysis because the 
emergence of other diseases would be very likely such as infection. Infection is 
common among chronic hemodialysed patients (Miller et al., 2016). Hence, 
leucocyte level should be checked before hemodialysis commenced especially if 
patients were prescribed antibiotic due to infection (Miller et al., 2016). In achieving 
the good clinical outcomes, patients should get good treatment based on the guideline 
provided by Kidney Disease Outcomes Quality Initiative (KDOQI).  
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Indonesia and Malaysia are the neighboring countries with similarities such 
as  dietary habit and the high incidence of renal failure (Indonesian renal Registry, 
2012; ). Most of the ESRD patients in both countries have diabetic and/ hypertensive 
as the cause of renal failure (Indonesian Renal Registry, 2012) (Ministry of Health 
Malaysia, 2013) but the clinical outcomes relate to mortality incidence might be 
different between both countries. 
Malaysia is the closest country to Indonesia where the more attention given to 
nephrology disease. It is proven by the detail report of National Renal Registry 
(NRR) and the availability of the complete information from Malaysian Society 
Nephrology about nephrology field. 
Indonesia is one of the countries with high prevalence of hemodialysed 
patients (Indonesian Renal Registry, 2014).   Lack of publication on clinical practice 
in Indonesia is one of the challenges in this research. Clinical practice is one of the 
factors that determine mortality rate and clinical outcome of the treatment.  
The duration of hemodialysis is closely related to the efficiency and adequacy 
of hemodialysis, so long hemodialysis is  influenced by the rate of progression of 
uremia due to worsening of renal function and comorbidity factors, as well as the 
speed of blood flow and dialysate flow rate (National Kidney Foundation, 2002). 
There are 3 groups of hemodialysis duration per session in Indonesia; < 3 
hours, 3-4 hours and > 4 hours per session. In this report, it was discovered that 
hemodialysis duration for category 3-4 hours per session had the biggest number in 
hemodialysed patients also for 2 times frequency of hemodialysis per week, it should 
be more than 5 hours per session in term of hemodialysis duration (Indonesian Renal 
Registry, 2014).  
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In Malaysia, there are 6 groups of hemodialysis duration per session; <= 3 
hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours and > 5 hours. In 2012, almost 98.1% 
(25,247 of 25,739 patients) of Malaysian hemodialysed patients had hemodialysis 3 
times per week however 98.8%  (25,429 of 25,742 patients) did hemodialysis 4 hours 
per session (National Renal Registry Malaysia, 2013).  
According to the Association of nephrologist in Indonesia (Pernefri) 
recommendation, isolation and using special hemodialysis machine are not necessary 
for hemodialysed patients who has been infected by hepatitis C viral 
(Recommendation for controlling hepatitis B and hepatitis C viral infection by 
Pernefri) while Ministry of Health Malaysia recommends that hemodialysed patients 
who has been infected by hepatitis C viral will be dialyzed in a separate room or a 
separate area with a fixed partition and dedicated machines. 
Furthermore, a study conducted in Indonesia showed 15353 (0.006%) new 
patients  undergone hemodialysis in 2011 and increased to 19621 (0.008%) patients 
in 2012 (Indonesian renal Registry, 2012). In Malaysia, indicated 5930 (0.020%) 
new hemodialysed patients in 2011 but it was decreased slightly at 5830 (0.019%) 
patients in 2012 (National Renal Registry Malaysia, 2013). Indonesia increased  at 
33.3% while Malaysia descended at 5 % in the same time at 2012 (Indonesian renal 
Registry, 2012; Ministry of Health Malaysia, 2013).
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1.1 Prevalence of Mortality of Hemodialysed patients in the World 
 
According to the World Health Organization (2005)  approximately 35 
million people died due to chronic kidney disease (Levey et al., 2007). The 
prevalence of ESRD in the world were more than 2 million people (Ortiz et.al., 
2014). Unadjusted 5-year survival of all patients with ESRD (treated with dialysis or 
transplantation) was 41% in the USA, 48% in Europe and 60% in Japan for patients 
with ESRD onset between 2004 and 2008 (Robinson et al., 2016). Infection was the 
primary cause of death among hemodialysed patients and it was followed by 
cardiovascular as a secondary cause for mortality among these patients (Ortiz et al., 
2014). 
1.3 Prevalence of Mortality of Hemodialysed patients in Indonesia 
 
Indonesian Renal Registry (IRR, 2012) described that mortality cause due to 
cardiovascular and cerebrovascular were 1557 patients and 395 patients among 3332 
hemodialysed patients respectively (Indonesian Renal Registry, 2012). The largest 
causes of death was cardiovascular (1090 patients) and it was followed by 
cerebrovascular (233 patients) among 2221 all hemodialysed patients (Indonesian 
Renal Registry, 2014).  
In 2014, one-month survival of all hemodialysed patients in Indonesia was 
87.3% while one-year survival was 46.7% in 2014 (Indonesian Renal Registry, 
2014). The reason and the percentage of patients who discontinued hemodialysis in 
2014 are 49% died, 25% for unknown reason, 23% dropped out and only 1% 
changed the hemodialysis method to peritoneal dialysis or to the renal transplantation 
(Indonesian Renal Registry, 2014). 
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1.4 Prevalence of Mortality of Hemodialysed patients in Malaysia 
 
The Malaysian dialysis & transplant 20th reported that 3017 hemodialysed 
patients died in 2012 while some of them were caused by cardiovascular (977 
patients) and  441 patients died at home (National Renal Registry Malaysia, 2013).  
The death rate increased in 2013 with 3437 patients, some of the death were caused 
by cardiovascular (1213 patients) (National Renal Registry Malaysia, 2013). 
In 2012, in 6966 patients who were on dialysis have shown survival in 6010  
patients by the end of one-year survival function. Furthermore, in 2013, almost 6683 
patients showed better survival of  87% in patients registered from 2011 (National 
Renal Registry Malaysia, 2013). 
 
1.2 Therapeutic Outcomes of Hemodialysed patients 
 
Usually, hemodialysed patients have hypertensive, diabetic, anemia, mineral & 
bone disorder and Cardiovascular Disease (CV). As mentioned in the background, 
diabetic and/ hypertensive are the most cause of the ESRD. For hypertensive, 
aggressive blood pressure control is one way  to delay the decline in renal function in 
patients with Chronic Kidney Disease (CKD) (Aram V. Chobanian, George L, 
Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo, 2004).  
Antihypertensive therapy prevents kidney damage and slow the rate of 
progression of CKD in both diabetic and No-diabetic Patients (Kidney Disease 
Outcomes Quality Initiative, 2004). For diabetic, the majority of drugs available to 
treat hyperglycemia, and especially first-generation sulfonylureas and a-glucosidase 
inhibitors, are affected by kidney function and therefore should be either be avoided 
or used in reduced doses by patients with CKD (Cavanaugh, 2007). 
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Anemia, mineral & bone disorder and cardiovascular disease are  
complications of ESRD (Marry Anne & Alledredge, 2013). Anemia may develop 
early during the course of CKD due to inadequate synthesis of erythropoietin by the 
kidneys (Arora, 2016). Both iron supplementation and injectable erythropoiesis-
stimulating agents (ESAs) have been used to correct anemia (Besarab & W.Coyne, 
2010). With erythropoietin treatment, the goal is a hemoglobin level of 10-12 g/dL, 
as normalization of hemoglobin in patients with CKD stages 4-5 has been 
associated with an increased risk of adverse outcomes when patients use EPO in 
high dose (Arora, 2016). 
Treatment of abnormal mineral homeostasis in patients with CKD includes 
the following (National Kidney Foundation, 2009) are lowering high serum 
phosphorus levels, maintaining serum calcium levels and lowering serum 
parathyroid hormone levels. 
Patients with CKD are at high risk for developing CVD complication; the 
risk increases as estimated glomerular filtration rate (eGFR) declines. CVD is the 
leading cause of mortality in CKD (National Kidney Disease Education Program, 
2015). Adults aged 50 years or above with an estimated glomerular filtration rate 
(GFR) of less than 60 mL/min/1.73 m2 who are not being treated with in long-term 
dialysis or kidney transplantation are treated with a statin or a statin plus ezetimibe 
(Barclay, 2013).  
Adults aged 18-49 years with an estimated GFR of less than 60 
mL/min/1.73m2 who are not being treated with dialysis or kidney transplantation 
are treated with statins if they have coronary disease, diabetes, prior ischemic 
stroke, or an estimated 10-year incidence of coronary death or no fatal-myocardial 
infarction exceeding 10%  (Barclay, 2013). 
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1.3 Research Question 
 
  The background of this study has explained the big issue in term of 
hemodialysis  not only the prevalence but followed by the rising  mortality among 
those patients. The mortality incidence can be controlled by the good therapeutic 
outcome. Few publication about the comparison study on hemodialysis especially 
between two Asian countries has created some questions which needs to be 
answered; 
1) The comparison of therapeutic results and expected clinical outcomes 
achieved among diabetic and/or hypertensive patients who undergo 
hemodialysis in both countries. 
2) Evaluation of the rate of mortality among hypertensive and diabetic patients 
who undergo hemodialysis in Indonesia and Malaysia. 
1.4 Rationale of the study 
 
ESRD is burdensome on public health. Prevalence and mortality associated 
with ESRD depends on the treatment and clinical practice. Each hospital has 
difference clinical pattern on treatment, hence gives impact to quality of life and 
clinical outcome. Causal factors of ESRD could be sources of severe of disease 
although complications that occur during hemodialysis treatment might be the main 
thing of it. Before that, the good pharmacotherapy given must be the priority to 
achieve the good clinical outcome.  
Kidney Disease Outcomes Quality Initiative (KDOQI) is one of the 
worldwide guideline for kidney disease patients although each country has their own 
guideline still refers to KDOQI guideline. Having the guideline provide assumption 
that the treatment should be going well but some facts tell opposite due to 
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unexpected factors. Better treatment or improve treatment outcome only can be done 
by evaluating the clinical practice from comparative between two hemodialysis 
centrals. Jakarta and Penang are big cities that also have big hemodialysis center 
which is expected to help in evaluating the predictors of mortality that can affects 
better treatment outcomes. 
1.5 Significant of the study 
 
This is the first study which compared therapeutic outcome and mortality 
between two Asian countries (Indonesia and Malaysia) done in two HD centers 
(Jakarta, Penang). This research involves two types of data/samples (retrospective 
and prospective). Retrospective samples were done by taking data of hemodialysed 
patients who had died last five years and prospective samples were collected by 
following and evaluating hemodialysed patients for 9 months in both countries. 
This research may help in evaluating of clinical practice, treatment outcomes 
and predictors of mortality. Previous studies in Malaysia reported mortality factors 
among hemodialysis covering only few factors such as coronary heart disease, 
peripheral vascular disease, acute myocardial infarction and congestive heart failure 
(N. B. Yusop, Mun, Shariff, & Huat, 2013). National Renal Research (NRR) report 
of all of kidney disease treatment outcome in Malaysia does not give the detail on all 
incidence going on and such as improving or decreasing of mortality incidence, the 
relationship between practice pattern and clinical outcome and others causal factors 
which correlate with mortality but Malaysia has their own guideline in term of 
hemodialysis and research about hemodialysis are conducted regularly. However, 
with Indonesia, general information is provided about hemodialysis by the Indonesia 
Renal Registry report but there is lack of published article related to hemodialysis 
among hemodialysed patients in Indonesia. 
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In this research, the first objective, quality of life patients for a hemodialysis 
center in Penang, the evaluation was carried out by using Kidney Disease Quality of 
Life (KDQOL)-24 questionnaire which was adopted from KDQOL-24 Malaysian 
version while for a hemodialysis center in Jakarta, KDQOL-24 questionnaire 
translated to Indonesian language was used for pilot study to assess the validity of 
the questionnaire. 
The other objectives such as clinical pattern, causal factors, complications, 
clinical outcome and mortality rate of hemodialysed patients for both hemodialysis 
center were collecting by assessing retrospective and prospective data. 
1.6 Objectives  
 
Due to the novelty comparative study about therapeutic outcome and mortality 
among hemodialysed patients between two Asian countries, general objective was 
about evaluation related to these issues in both countries. As mentioned on the 
research questions, therapeutic outcomes and mortality rate among hypertensive and 
diabetic patients was evaluated for providing answer to clinical outcome achieved in 
these both countries. 
1.6.1  General Objective 
 
Evaluation of the clinical outcomes and mortality rate among hypertensive 
and diabetic patients on hemodialysis between Indonesia and Malaysia. 
1.6.2  Specific Objectives 
 
Specific objectives of this study were created based on the elaboration of the 
general objective. Demographic data was the first thing that was explored because 
the study was conducted in two Asian countries. Besides that, few things like clinical 
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pattern, quality of life patients, potential risk factors, differences of the 
pharmacotherapy, potential complications and mortality rate was included as the 
specific objectives which has been conducted to answer the clinical outcome 
achieved in these two Asian countries. The specific objectives answered on this study 
are; 
 
1) Evaluation of demographic data of patients and practice pattern that correlate 
with the clinical outcome among hypertensive and diabetic patients on 
hemodialysis for Indonesia and Malaysia. 
2) Assessment of the health-related quality of life (HRQOL) patients using 
KDQOL (Kidney Disease Quality of Life)-24 tool. 
3) Evaluation of the potential risk factors of ESRD that correlate with the 
clinical outcome among hypertensive and diabetic patients on hemodialysis 
between Indonesia and Malaysia. 
4) Evaluation of the differences of pharmacotherapy among ESRD patients who 
undergone hemodialysis between Indonesia and Malaysia. 
5) Evaluation of the potential complications that occur among ESRD patients 
who undergo hemodialysis and the mortality rate in both countries. 
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CHAPTER 2 LITERATURE REVIEW 
 
 
2.1 Hemodialysis 
 
End-stage renal disease can be treated by renal replacement therapies, such as 
Hemodialysis (HD), Transplantation, and Peritoneal Dialysis (PD) (Indian Society of 
Nephrology, 2014). HD increases expected lifetime of the patients minimizing the 
effects of neurological complications (Denhaerynck, 2007; Goksan, Kaarali-Savrun, 
Ertan, & Saurun, 2004) and improves serum creatinine, albumin and prealbumin, 
normalises the protein catabolic rate (nPCR) as well as increases the dietary intake of 
patients (N. B. M. Yusop, Mun, Shariff, & Huat, 2013). Despite its advantages, HD 
is highly associated with malnutrition and lower quality of life (QOL) (T. Chang, 
Nam, Shin, & Kang, 2015). Severe malnutrition among HD patients in Malaysia was 
reported to be approximately 4.6% - 19%, while 72% - 90.9% are mildly 
malnourished (N. B. M. Yusop et al., 2013). Hemodialysis dose given is generally 2 
times a week with each hemodialysis for 5 hours or as many as three times a week 
with each hemodialysis for 4 hours (Goksan et al., 2004).  
 
2.2 Background progression of CKD to ESRD 
 
Chronic Kidney Disease (CKD) is defined as kidney damage or Glomerular 
Filtration Rate (GFR) < 60 ml/min/ 1,73 m2 for 3 months or more, irrespective of 
cause (Draws, P; Rahman, 2009; Levey, et.al, 2005). Evidence of kidney damage, 
including persistent albuminuria—defined as > 30 mg of urine albumin per gram of 
urine creatinine (Grimshaw & Eccles, 1998). To understand the background of CKD 
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to ESRD, identification of CKD progression, risk factors, symptoms and signs of 
CKD was discussed. 
2.1.1 Identification of CKD Progression 
 
CKD can be classified into two (2) categories; GFR and albumin category. 
For GFR category calculation, filtration rate of the wastes of metabolism in 
glomerular need to be calculated while albumin value can be seen directly from the 
result of laboratory value of the patients.  
2.2.1.1 GFR Category 
 
GFR category consist of five (5) stages. There are 1 to 5 where stage 3 can 
be divided into stage 3A and 3B. For patients who have GFR category in stage 5, 
kidney failure is showed with GFR less than 15 ml/min/1.73 m2. They are referred to 
End-Stage Renal Disease (ESRD) patients. Progression of chronic kidney disease is 
in the last stage and the stage kidney does not function anymore. Classification of 
CKD can be seen in Table 2.1 below; 
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Table 2.1 Classification of Chronic Kidney Disease by GFR Category*  
Stage Description GFR 
(ml/min/1,73 m2) 
Related Terms 
1 Kidney Damage with normal or 
increasing of GFR 
≥ 90 Albuminuria, 
Proteinuria, 
Hematuria 
2 Kidney damage with mild 
reducing of GFR 
60-89 Albuminuria, 
Proteinuria, 
Hematuria 
3 A Midly to moderately decrease 40-59 Chronic Renal 
Insufficiency,  
3B Moderately to severely 
decreased 
30-44 Early Renal 
Insufficiency 
4 Severe reducing of GFR 15-29 Chronic Renal 
Insufficiency, Late 
Renal 
Insufficiency, Pre-
ESRD 
5 Kidney Failure < 15 (or dialysis) Renal failure, 
Uremia, End-
Stage Renal 
Disease 
*Adopted from Journal Annals of Internal Medicine, Kidney International, 
Faculty Group Practice University of Michigan Health System (UMHS) (Draws, 
P; Rahman, 2009; Levey, A.S., et.al, 2005; Lukela & et.al, 2014) 
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2.2.1.2 Albumin Category 
 
Albumin category consist of three (3) stages. There are stage A1, A2 and A3. 
Stage A3 shows the severe of kidney condition but for stage A1 shows mild of 
kidney condition. This can be seen in Table 2.2 below: 
Table 2.2 Classification of Chronic Kidney Disease by Albumin Category* 
Stage Description Albumin  
A1 Normal to mildly increased < 30 mg/g 
< 3 mg/mmol 
A2 Moderately increased 30-300 mg/g 
3- 30 mg/mmol 
A3 Severely increased              > 300 mg/g 
          > 30 mg/mmol 
 *Adopted from National Kidney Foundation (NKF, 2013) 
 
2.2.2 Risk Factors of CKD 
 
Risk factors is an alarm pointing to worst condition that may happen for CKD 
patients. In this case, information about risk factors on CKD is very important in 
other to avoid severity of ESRD. People who are not aware of the risk factors, signs 
and symptoms of CKD may be a victim of ESRD patients in future. 
There are four (4) categories of risk factors. They are susceptibility, initiation, 
progression and end-stage factors. Susceptibility factors depend on 
sociodemographic variables such as age, family history and race. An initiation 
factors depend on the disease such as metabolic disorder, infection, autoimmune and 
drug toxicity, while, progression factors depend on the severity of the metabolic 
disorder such as the higher blood pressure, higher proteinuria and poor glycemic 
control and End-stage factors depend on lack of attention to the progression factors 
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such as lower dialysis dose and high serum phosphorus (Levey.et.al, 2005). This can 
be seen in Table 2.3 below; 
Table 2.3 Risk Factors for CKD* 
No Component Causal 
1 Susceptibility Factors  Older Age 
 Family History of CKD 
 Reduction in Kidney Mass 
 Low Birth Weight 
 Racial or Ethnic Minority Status 
 Low Income/ Low EduCation 
 
2 Initiation Factors  Diabetes 
 High Blood Pressure 
 Autoimmune Diseases 
 Systemic Infections 
 Urinary Tract Infections 
 Urinary Stones 
 Lower Urinary Tract Obstruction 
 Drug Toxicity 
 Heredity Disease 
 
3 Progression Factors  Higher Level of Proteinuria 
 Higher Blood Pressure Level 
 Poor Glycemic Control in Diabetes 
 Possibly Dislipidemia 
 Smoking 
 
4 End-Stage Factors  Lower Dialysis Dose 
 Temporary Vascular Access 
 Anemia 
 Low Serum Albumin 
 High Serum Phosphorus 
 Late Referral to the hospital 
 
*Adopted from Journal Kidney International and National Kidney Foundation 
(Levey, et.al, 2005; NKF, 2002) 
 
2.2.3 CKD Signs and Symptoms  
 
There are two stages of CKD; early and late stages of CKD. To avoid the 
severe of the disease, it is important to be aware of the early stages of CKD signs and 
symptoms.  Nausea, edema, pale skin and foamy or bubbly urine are the examples of 
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early stages of CKD. Elevated blood pressure, stomatitis and anemia are examples of 
the late stages of CKD. This can be seen in Table 2.4 below; 
 
Table 2.4 Symptoms and Signs of CKD* 
No Component Causal 
1 Symptoms and 
Signs of Early 
Stages of CKD 
 Weakness 
 Decreased appetite 
 Nausea 
 Changes in urination (polyuria, frequency) 
 Blood in urine or dark-colored urine 
 Foamy or bubbly urine 
 Loin pain 
 Edema 
 Elevated blood pressure 
 Pale skin 
 
 
2 Symptoms and 
Signs of Late 
(Uremic) Stages of 
CKD 
 General (lassitude , fatigue , elevated 
blood pressure , signs of volume overload , 
decreased mental acuity , intractable 
hiccups , uremic fetor ) 
 Pulmonary (dyspnea , pleural effusion , 
pulmonary edema , uremic lung ) 
 Cardiovascular (periCardial friction rub 
,congestive heart failure ) 
 Gastrointestinal ( anorexia , nausea , 
vomiting, weight loss , stomatitis , 
unpleasant taste in the mouth ) 
 Neuromuscular ( muscular twitches , 
peripheral sensory and motor 
neuropathies, muscle cramps , restless legs 
,sleep disorders , hyperrefl exia , seizures , 
encephalopathy , coma ) 
 Endocrine-metabolic ( decreased libido , 
amenorrhea , impotence ) 
 Hematologic ( anemia , bleeding diathesis 
) 
 
 *Adopted from book “Management of Chronic Kidney Disease” Springer 
(Choi, 2012) 
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2.2.4 Comorbidities of CKD 
 
Hypertension (prevalence 74.5 million in the world) and diabetes (prevalence 
23.6 million in the world) are the two most important CKD risk (Abboud & 
Henrich, 2010; Clinical Practice Recommendations for Primary Care Physicians and 
Healthcare Providers, 2011) when advanced, it causes a higher risk of mortality 
(Abboud & Henrich, 2010).  
Overall, diabetic prevalence population in the world among ESRD (44%) and 
HTN (28%) (Clinical Practice Recommendations for Primary Care Physicians and 
Healthcare Providers, 2011). Together, these two disorders constitute 72% of the 
causes of ESRD (Clinical Practice Recommendations for Primary Care Physicians 
and Healthcare Providers, 2011).  
 
2.2.4.1 Diabetes Mellitus    
 
Diabetes is the commonest cause of ESRD requiring renal replacement 
therapy (Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamier J, 1997; SIGN, 
2008). From all-cause  ESRD in USA, men with diabetes are more than 12 times 
greater per year than in men without diabetes (199.0 vs 13.7 cases per 100,000 
person years; relative risk (RR) 12.7; 95% confidence interval (CI), 0.5 to 15.4) 
(BranCati FL, Whelton PK, Randall BL, Neaton JD, Stamier J, 1997; SIGN, 2008). 
This increased incidence was attributable to both diabetic and non-diabetic 
nephropathy. In 2005, 0.5% of the population with diabetes who were recorded in the 
National Diabetes Survey were reported had ESRD complication (Brancati FL, 
Whelton PK, Randall BL, Neaton JD, Stamier J, 1997; SIGN, 2008).  
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The connection between kidney and insulin metabolism was well known for 
many years (Biesenbach & Pohanka, 2011; Horton, Johnson, & Lebovitz, 1968). For 
insulin excretion the kidneys are one of its target organs (Iglesias & Díez, 2008). 
Chronic renal failure was associated to multiple alterations in the carbohydrate and 
insulin metabolism that should be taken into account when treating diabetic patients 
with altered renal function (Biesenbach & Pohanka, 2011; Defronzo, Andres, Edgar, 
& Walker, 1973). Effects of kidney dysfunction in dialysis patients who have 
diabetics are hypoglycemia and hyperglycemia (Rhee et al., 2015).  Monitoring of 
glycemic control among dialysis patients is important to avoid those effects. 
Specific therapeutic needs (oral agents or insulin) will be determined based 
on the degree of insulin resistance or insulin deficiency of patients with renal 
insufficiency (Biesenbach & Pohanka, 2011; Rabkin, Ryann, & Duckwords, 1984). 
A good metabolic control is not only important in the early phase of diabetic 
nephropathy but also in diabetic patients with ESRD (Biesenbach & Pohanka, 2011). 
It was shown in several studies, that metabolic control under antidiabetic therapy is a 
predictor for prognosis of patents with renal replacement therapy (Biesenbach & 
Pohanka, 2011; Morioko, Etmoto, T, & et.al, 2001). A good glycemic control can 
reduce the progression of atherosclerosis (Biesenbach & Pohanka, 2011; Oomichi, 
Etmoto, Tabata, & et.al, 2006) and improve the survival in patients treated with 
hemodialysis (Biesenbach & Pohanka, 2011; C. Kovesdy, Sharma, & Kalandar, 
2008). Though, in another study it was suggested that aggressive glycemic control 
cannot be routinely recommended for all diabetic hemodialysed patients on the basis 
of reducing mortality risk (Biesenbach & Pohanka, 2011; William, 2007).  
The majority of uremic type 2-diabetic patients need insulin, however, a 
smaller part of these diabetic patients can also be treated with oral antidiabetic agents 
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(Biesenbach & Pohanka, 2011). Some studies suggest avoiding long-acting insulin, 
whereas others support its use (Cavanaugh, 2007; Synder & Berns, 2004). One small 
study comparing type 1 diabetic patients with and without Diabetic Kidney Disease 
(DKD) demonstrated that clearance was reduced for both regular insulin and insulin 
lispro; however, the effect of regular insulin was also impaired in patients with DKD 
(Cavanaugh, 2007; Rave, Heise, Pfutzner, Heinemann, & Sawicki, 2001).  
Thus, a higher dose of regular insulin may be required, despite lower 
clearance in patients with kidney disease. Insulin lispro did not demonstrate any 
differences in metabolic effects on glucose in patients with or without Diabetic 
Kidney Disease (DKD) (Cavanaugh, 2007; Rave et al., 2001). Regardless of the form 
of insulin chosen to treat diabetes, caution must be exercised when administering 
therapy to patients with kidney disease and frequent blood glucose monitoring may 
be used to adjust dosing and prevent hypoglycemia (Cavanaugh, 2007) 
In 2001, more than 91 million prescriptions were written for oral 
hyperglycemic agents, and ~ 33% were for sulfonylureas (Cavanaugh, 2007; 
Wysowski, Armstrong, & Governale, 2003). The clearance of both sulfonylureas 
and its metabolites was highly dependent on kidney function, and severe prolonged 
episodes of hypoglycemia as a result of sulfonylurea use have been described in 
dialysis patients (Cavanaugh, 2007; Krepinsky, Ingram, & Clase, 2000). In patients 
with stages 3–5 CKD, first-generation sulfonylureas should be avoided. Of the 
second-generation sulfonylureas, glipizide was recommended because its 
metabolites are not active, and there was a lower potential for development of 
hypoglycemia (Gennari, Hood, Greene, Wang, & Levey, 2006). 
Metformin is in the biguanides class of oral hyperglycemic drugs, which does 
not exhibit the high risk of hypoglycemia associated with other drug classes used to 
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treat diabetes (Cavanaugh, 2007). However, special care must be taken when it is 
used in patients with CKD. There was a risk of development of lactic acidosis, even 
in patients with mild impairment of kidney function, again likely resulting from the 
accumulation of the drug and its metabolites (Cavanaugh, 2007; Davidson & Peters, 
1997). Metformin was contraindicated in male patients with a serum creatinine > 
1.5 mg/dl and in female patients with serum creatinine > 1.4 mg/dl (Cavanaugh, 
2007; Gennari et al., 2006) . 
Metformin was contraindicated with even mild to moderate kidney disease, 
whereas TZDs did not require dose adjustments for kidney disease and may have an 
independent beneficial impact on the progression of DKD (Cavanaugh, 2007). A 
summary of available drug therapies for diabetes and dosing recommendations was 
presented in Table 2.5. 
 Table 2.5 Drug Therapies and Dosing Recommendations for Dialysis Patients* 
No Administrative of 
Drugs Given 
Drug Therapies and 
Dosing 
Recommendations 
Notice 
1 Intra Peritoneal 
(IP) or Sub 
Cutaneous (SC 
Insulin = dose reduction 
of 50 % when GFR is < 
10 ml/min/1.73 1,2,3 
- 
2 Oral Sulfonilureas, 
Short acting glipizide 2,4 
Acetohexamide, 
Chlorpropamide, 
Tolazamide, 
Tolbutamide should 
not be used by dialysis 
patients due to of 
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hypoglycemia effect 
3 Oral Meglitinides, 
Repaglinide 2,4 
Nateglinide is not 
advised due to 
hypoglycemia effect 
4 Oral Biguanides Metformin is 90 % is 
renally excreted and it 
should not be used in 
dialysis patients 5 
5 Oral Thiazolidinediones 
(TZD) 
Pioglitazone reduced risk 
of Cardiovascular disease 
morbidity and mortality 
Overall this group is 
promote edema and 
congestive heart 
failure 
For example; 
Rosiglitazone have 
shown an increased 
risk of cardiovascular 
disease events 
6 Oral Dipeptidyl Peptidase-4 
Inhibitors (DPP-4 
Inhibitors) 
Sitagliptin 25 mg/day 
Saxagliptin 2.5 mg/day 
after dialysis 
Exenatide is not 
recommended in 
dialysis patients 
7 Oral Alpha Glucosidase 
Inhibitors 
Acarbose and Miglitol 
are not advised in 
23 
 
dialysis patients 
8 Oral Sodium Glucose 
Contransporter 2 
(SGLT2) Inhibitors 
Contraindicated  in 
dialysis patients due to 
modesty lower 
elevated blood glucose 
*Summarised from (Rhee et al., 2015); 1 (Kalantar-Zadeh, Derose, Nicholas, 
Sharma, & Kovesdy, 2009), 2 (Reilly & Berns, 2010), 3 (Charpentier, Riveline, & 
Varroud-Vial, 2000), 4 (Flynn & Bakris, 2013), 5 (KDIGO, 2012a) 
 
2.2.4.2 Hypertension / High Blood Pressure 
 
Hypertension (HTN) in CKD is considered by default as “resistant HTN”, ie, 
treatment requires 3 or more antihypertensive agents at maximally tolerated doses 
and one of which must be a diuretic (Indian Society of Nephrology, 2014). The 
typical Blood Pressure (BP) profile is a Systole Blood Pressure (SBP) greatly 
exceeding Diastole Blood Pressure (DBP), manifested as an elevated pulse pressure 
(>55 mmHg) (Indian Society of Nephrology, 2014). Either the SBP or pulse 
pressure may be increased in hypervolemic/edematous individuals who must often 
be treated with diuretics (Indian Society of Nephrology, 2014). Many studies have 
shown that hypertension is a risk factor for CKD  (Biesenbach & Pohanka, 2011; 
Chadban et al., 2003; Coresh, Astor, Greene, Eknoyan, & Levey, 2003; R. Foley et 
al., 2005; Fox et al., 2004; SIGN, 2008b). 
Management hypertension is recently referred to Eight Joint National 
Committee (JNC8) while blood pressure for patients with all ages CKD present with 
or without diabetes less than 140/90 mmHg (Nicole, Contino, Jain, Grand, & 
Hagans, 2015) while JNC 8 is the new guideline for hypertensive which all the 
physicians should follow. Initiate Angiotensin Converting Enzyme inhibitor (ACEi) 
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or Angiotensin Receptor Blocker (ARB), alone or combination with other drug class 
of hypertension is the hypertension treatment which should give to all the CKD 
patients.   
 
2.3 Baseline Assessments for Hemodialysis 
 
In order to conduct the baseline assessment for age, gender, height, weight, 
comorbidities (diabetes, peripheral vascular disease, coronary artery disease, 
congestive heart failure, cerebrovascular disease, cancer), and receipt of pre dialysis 
care (at least 4 months) must be recorded for each patients to obtain the baseline 
laboratory values (Williams, Quinn, Callery, Kiss, & Oliver, 2011). Baseline 
laboratory values (hemoglobin, serum creatinine, urea, albumin, calcium, phosphate, 
and urea reduction ratio) were the mean values of the first 3 months of dialysis 
measured during routine monthly blood work and this must be recorded for all HD 
and PD patients (Williams et al., 2011).  
Estimated glomerular filtration rate was also calculated from the last 
available serum creatinine prior to the start of dialysis (Williams et al., 2011). Access 
in use was recorded at the start of outpatient dialysis treatment (Williams et al., 
2011). Dialysis modality was assigned as either PD or HD at the start of outpatient 
dialysis and for a secondary analysis after 90 days of dialysis therapy (Williams et 
al., 2011). 
 
 
 
